Comparative cost and clinical effectiveness of clostridial collagenase ointment for chronic dermal ulcers

Abstract

Chronic dermal ulcers affect approximately 2.4-4.5 million people in the USA and are associated with loss of function, decreased quality of life and significant economic burden. Debridement is a critical component of wound care involving removal of nonviable tissue from chronic wounds to stimulate the granulation and epithelialization process. Clostridial collagenase ointment has been used as a method of wound debridement for more than 50 years and is currently the only enzymatic debriding ointment with US FDA approval. This review discusses the results of recent real-world studies that build upon the evidence demonstrating the clinical effectiveness, cost-effectiveness and safety of clostridial collagenase ointment across wound types and care settings.

Collagenases in medical practice: modern collagenase-based preparations and prospects for their improvement

“…Данные подтверждают, что мазь на основе коллагеназы является безопасным и эффективным средством для лечения кожных язв и ожоговых ран, способствующим уменьшению времени заживления и выраженности болевого симптома, снижению риска развития инфекции. Эффективность препарата «Сантил» для хирургической обработки раны диабетической стопы язв, пролежней и трофических варикозных язв, а также ожогов, была продемонстрирована в ряде клинических испытаний различных учреждениях (например, стационарный, амбулаторный и долгосрочный уход) [32][33][34].…”

Antlerogenic stem cells extract accelerate chronic wound healing: a preliminary study

“…In the United States only, costs directly related to treatment of chronic wounds were estimated at approx. $25 billion in 2007 [ 5 ] and at $33 billion in 2014 [ 6 ]. It is assumed that this number will continue to rise – due to the increasing life expectancy (as the risk of chronic wounds development increases with age) and the greater incidence of diabetes, obesity, bad nutrition, deep vein thrombosis, chronic diseases and others, which significantly impedes wound healing [ 6 – 8 ].…”

“…$25 billion in 2007 [ 5 ] and at $33 billion in 2014 [ 6 ]. It is assumed that this number will continue to rise – due to the increasing life expectancy (as the risk of chronic wounds development increases with age) and the greater incidence of diabetes, obesity, bad nutrition, deep vein thrombosis, chronic diseases and others, which significantly impedes wound healing [ 6 – 8 ]. Moreover, above calculations consider direct costs of treatment only, without taking into account the costs related to loss of productivity or restriction/exclusion from professional activity.…”

Ca2+‐induced orientation of tandem collagen binding domains from clostridial collagenase ColG permits two opposing functions of collagen fibril formation and retardation

“…The clostridial collagenases have been successfully used as a wound debridement for more than 50 years [17]. The intralesional injection of ColG and ColH was approved for use in the treatment of excessive connective tissue build up found in Dupuytren’s contracture and Peyronie’s disease [18].…”